xRead Articles - October 2022

Number of patients who are clinical responders (reduction in RSI by ≥ 6 points)

(Continues)

300 mg daily, maximum 600 mg BID None 4 weeks Cough severity score Modi fi ed LCQ None 3 months Subjective response to therapy

Number of patients improving on cough severity score

24-hr cough frequency (coughs/hr)

Limitation of symptoms on everyday activity

Clinician assessment of participant ability to

understand and implement strategies

electroglottographic analyses

Percent reduction in RSI, CSI from baseline

14 weeks LCQ Cough severity VAS

Capsaicin cough challenge Urge-to-cough scale

CAPE-V, DSI, LHQ, VHI

Acoustic and

4 sessions Symptom severity and frequency rating

analysis rated by SLPs

cough symptoms from baseline

4 sessions Perceptual voice

None 6 weeks RSI CSI

None 6 or more months Percent reduction of

pathology treatment (5 sessions) (20)

oral tablet with speech

intervention program (HLE) 30-min sessions (44)

Placebo

Healthy Lifestyle Education HLE

30-min sessions

Retrospective case series 32; 32 (8/24) 63 1st line tricyclic antidepressant : amitriptyline 10 mg daily,

29; 29 (9/20) 63 Trigger reduction method :

2nd line neuromodulator :

4th line neuromodulator : pregabalin

5th line neuromodulator : oxcarbazepine

66; 66 (18/48) NR Tricyclic antidepressant :

plant-based diet, standard re fl ux precautions, nasal saline irrigation 4 – 5 times

if failed all the above : capsaicin spray

3rd line selective serotonin reuptake inhibitor : citalopram

51; 35 (10/41) 47 Neuromodulator : gabapentin

Parallel RCT 40; 35 (13/27) E: 61 C: 64 Neuromodulator : pregabalin

maximum 80 mg daily (<60 yo); desipramine 10 mg

daily, maximum 80 mg daily (>60 yo)

amitriptyline 10 mg daily (minimum)

gabapentin 300 mg daily,

maximum 2400 mg daily

Parallel RCT 97; 87 (23/64) 59.4 SPEech Pathology Intervention Program for CHronic Cough (SPEICH-C) 30-min sessions (43) SPEICH-C Parallel RCT 97; 83 (22/61) E: 58.9 C: 61.5

titrated up to 300 mg daily, then tapered off with

speech pathology treatment (5 sessions) (20)

daily, intranasal steroid/

antihistamine combination

30-min sessions

case series

case series

case series

Stein et al (2013) Boston, MA, USA Retrospective Bastian et al (2015) Downers Grove, IL, USA

Australia

Australia

Australia

Zalvan et al (2019) Valhalla, NY, USA Retrospective

Leuven, Belgium Retrospective

Van de Kerkhove et al (2012)

Vertigan et al (2006) Newcastle, NSW,

Vertigan et al (2008) Newcastle, NSW,

Vertigan et al (2016) Newcastle, NSW,

Speech therapy

Laryngoscope 132: January 2022

Wamkpah et al.: Multimodal Treatments for Neurogenic Cough 113